Document:

EX-10.6

 Exhibit 10.6 
 AMENDED AND RESTATED CONSULTING AGREEMENT 
 (Omid Farokhzad) 

This Amended and Restated Consulting Agreement dated as of July 12, 2007 (this “Agreement”), is made by and between BIND
Biosciences, Inc., a Delaware corporation (the “Company”), and Omid Farokhzad (the “Consultant”). 
 WHEREAS, the Company and the Consultant are parties to a Consulting Agreement dated as of October 31, 2006 (the “Original Agreement”); and 

WHEREAS, the Company and the Consultant desire to amend and restate the Original Agreement as provided herein; 

NOW, THEREFORE, in consideration of the premises and the mutual covenants set forth herein, the parties hereby agree as follows:

 1. Consulting Services. 
 (a) The Company hereby retains the Consultant and the Consultant hereby agrees to perform such consulting and advisory services relating to the Field of Interest (as defined in Section 13G)) as the
Company may request and as set forth in Schedule A (the “Consulting Services”). 
 (b) The Consultant
agrees to make himself available to render the Consulting Services, at such times and locations as may be mutually agreed, from time to time as requested by the Company. Except as provided in Schedule A, the Consultant may deliver the
Consulting Services over the telephone, in person or by written correspondence. 
 (c) The Consultant agrees to devote his best
efforts to performing the Consulting Services. The Consultant shall comply with all rules, procedures and standards promulgated from time to time by the Company with regard to the Consultant’s access to and use of the Company’s property,
information, equipment and facilities. 
 (d) The Company acknowledges that (i) the Consultant is a member of the faculty
of Harvard Medical School (“Harvard”); (ii) the Consultant is subject to certain policies of Harvard, as such policies may be revised from time to time, including among others, policies concerning consulting, conflicts of
interest and commitment, intellectual property, and use of Harvard’s name; and (iii) any provision of this Agreement that conflicts with such policies shall be superseded by such policies. Further, the Company agrees that this Agreement is
subject to the Addendum attached hereto, the terms of which are incorporated herein by reference. 
 2.
Compensation. The Company shall pay the Consultant a consulting fee as provided in Schedule A. The Company will reimburse the Consultant for reasonable business expenses incurred by the Consultant in the performance of Consulting
Services for the Company as provided in Schedule A. 

 3. Independent Contractor. In furnishing the Consulting Services, the Consultant
understands that he will at all times be acting as an independent contractor of the Company and, as such, will not be an employee of the Company and will not by reason of this Agreement or by reason of his Consulting Services to the Company be
entitled to participate in or to receive any benefit or right under any of the Company’s employee benefit or welfare plans. The Consultant also will be responsible for paying all withholding and other taxes required by law to be paid as and
when the same become due and payable. Consultant shall not enter into any agreements or incur any obligations on behalf of the Company. 
 4. Term. The parties may terminate this Agreement with the mutual consent of both parties. The Company may terminate this Agreement at any time for Cause (as defined in Section 13U)) or at any
time after April 30, 2010 without Cause; provided, however, that in the event this Agreement is terminated by the Company without Cause, then the Company shall (i) deposit into escrow with an escrow agent acceptable to both parties
an amount of cash equal to the consulting fee paid to the Consultant during the preceding ninety (90) days, and (ii) cause the escrow agent to pay such amount to the Consultant payable when and as if Consultant had continued to provide
Consulting Services to the Company during the ninety (90) days immediately following such termination. The Consultant may terminate this Agreement for any reason; provided, however, that he shall first provide written notice to the
Company at least 30 days prior to the effective date of termination. 
 5. Exceptions to this Agreement. 

(a) Certain Other Contracts and Obligations. The Company acknowledges that (I) the Consultant is a member of the faculty of
Harvard and a member of the staff of The Brigham and Women’s Hospital (“Brigham”), and (II) the Consultant is now or may become a party to agreements with Harvard and/or Brigham and other third parties relating to the
disclosure of proprietary information, the ownership of discoveries and inventions, restrictions against competition and/or similar matters. The Consultant represents and agrees that the execution, delivery and performance of this Agreement does not
and will not conflict with any other agreement, policy or rule applicable to the Consultant. The Consultant will not (i) disclose to the Company any information that he is required to keep secret pursuant to an existing confidentiality
agreement with Harvard, Brigham or any other third party, (ii) use the funding, resources, facilities or inventions of Harvard, Brigham or any other third party to perform the Consulting Services, or (iii) perform the Consulting Services
in any manner that would give Harvard, Brigham or any other third party rights to any intellectual property created in connection with such Consulting Services. 
 (b) Prior Inventions. The Consultant has informed the Company, in writing, of any and all inventions which he claims as his own or otherwise intends to exclude from this Agreement because it was
developed by him prior to the date of this Agreement. The Consultant acknowledges that after execution of this Agreement he shall have no right to exclude any Company Inventions (as defined in Section 7) from this Agreement. The provisions of
this Section 5(b) shall not apply to, and the definition of Company Inventions in Section 7 shall not be understood to include, any invention or other form of intellectual property made or developed by the Consultant in connection with his
activities as a faculty member of Harvard or that are otherwise subject to the intellectual property policies of Harvard. 

  
 - 2 -

 6. Confidential Information. While providing the Consulting Services to the Company
and thereafter, the Consultant shall not, directly or indirectly, use any Confidential Information (as defined below) other than pursuant to his provision of the Consulting Services by and for the benefit of the Company, or disclose to anyone
outside of the Company any such Confidential Information. The term “Confidential Information” as used throughout this Agreement shall mean all trade secrets, proprietary information and other data or information (and any tangible
evidence, record or representation thereof), written or oral, whether prepared, conceived or developed by a consultant or employee of the Company (including the Consultant) or received by the Company from an outside source, which is in the
possession of the Company (whether or not the property of the Company) and which is maintained in secrecy or confidence by the Company. Without limiting the generality of the foregoing, Confidential Information shall include: 

(a) any idea, improvement, invention, innovation, development, concept, technical data, design, formula, device, pattern, sequence,
method, process, composition of matter, computer program or software, source code, object code, algorithm, model, diagram, flow chart, product specification or design, plan for a new or revised product, sample, compilation of information, or work in
process, or parts thereof, and any and all revisions and improvements relating to any of the foregoing (in each case whether or not reduced to tangible form); and 
 (b) the name of any customer, supplier, employee, prospective customer, sales agent, supplier or consultant, any sales plan, marketing material, plan or survey, business plan or opportunity, product or
development plan or specification, business proposal, financial record, or business record or other record or information relating to the present or proposed business of the Company. 

Notwithstanding the foregoing, the term Confidential Information shall not apply to information which (i) the Company has
voluntarily disclosed to the public without restriction or which has otherwise lawfully entered the public domain; (ii) was already properly and lawfully in the Consultant’s possession at the time it was received from the Company, as
evidenced by the Consultant’s written records; (iii) was or is lawfully received by the Consultant from a third party who was under no obligation of confidentiality respect thereto; (iv) was or is independently developed by Consultant
without reference to Company Confidential Information, as evidenced by the Consultant’s written records; or (v) is required to be disclosed by law, regulation or judicial or administrative process. 

The Consultant acknowledges that the Company from time to time has in its possession information (including product and development plans
and specifications) which is claimed by others to be proprietary and which the Company has agreed to keep confidential. The Consultant agrees that all such information shall be Confidential Information for purposes of this Agreement. 

The Consultant agrees that all originals and all copies of materials containing, representing, evidencing, recording, or constituting any
Confidential Information, however and whenever produced (whether by the Consultant or others), shall be the sole property of the Company. 

  
 - 3 -

 7. Inventions. Subject to the Consultant’s obligations to Harvard and Brigham,
the Consultant agrees that all Confidential Information and all other discoveries, inventions, ideas, concepts, trademarks, service marks, logos, processes, products, formulas, computer programs or software, source codes, object codes, algorithms,
machines, apparatuses, items of manufacture or composition of matter, or any new uses therefor or improvements thereon, or any new designs or modifications or configurations of any kind, or works of authorship of any kind, including, without
limitation, compilations and derivative works, whether or not patentable or copyrightable, conceived, developed, reduced to practice or otherwise made by the Consultant, either alone or with others, and in any way related to the Field of Interest or
to tasks assigned to the Consultant during the course of his relationship with the Company, whether or not conceived, developed, reduced to practice or made on the Company’s premises (collectively “Company Inventions”), and any
and all services and products which embody, emulate or employ any such Company Invention or Confidential Information shall be the sole property of the Company and all copyrights, patents, patent rights, trademarks and reproduction rights to, and
other proprietary rights in, each such Company Invention or Confidential Information, whether or not patentable or copyrightable, shall belong exclusively to the Company. The Consultant agrees that all such Company Inventions shall constitute works
made for hire under the copyright laws of the United States and hereby assigns and, to the extent any such assignment cannot be made at the present time, agrees to assign, to the Company any and all copyrights, patents and other proprietary rights
he may have in any such Company Invention, together with the right to file and/or own wholly without restrictions applications for United States and foreign patents, trademark registration and copyright registration and any patent, or trademark or
copyright registration issuing thereon. 
 8. Consultant’s Obligation to Keep Records. Consultant shall make and
maintain adequate and current written records of all Company Inventions, and shall disclose all Company Inventions promptly, fully and in writing to the Company immediately upon development of the same and at any time upon request. 

9. Consultant’s Obligation to Cooperate. The Consultant will, at any time during or after the term of this Agreement, upon
request of the Company, execute all documents and perform all lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement. Without limiting the generality of the
foregoing, the Consultant will assist the Company in any reasonable manner to obtain for its own benefit patents or copyrights in any and all countries with respect to all Company Inventions assigned pursuant to Section 7, and the Consultant
will execute, when requested, patent and other applications and assignments thereof to the Company, or Persons (as defined in Section 13U)) designated by it, and any other lawful documents deemed necessary by the Company to carry out the
purposes of this Agreement, and the Consultant will further assist the Company in every way to enforce any patents and copyrights obtained, including testifying in any suit or proceeding involving any of said patents or copyrights or executing any
documents deemed necessary by the Company, all without further consideration than provided for herein. It is understood that reasonable out-of-pocket expenses of the Consultant’s assistance incurred at the request of the Company under this
Section will be reimbursed by the Company. 
 10. Noncompetition. Subject to written waivers that may be provided by the
Company upon request, which shall not be unreasonably withheld, the Consultant agrees that 

  
 - 4 -

 
during the term of this Agreement and for a period of one year after the termination of this Agreement, the Consultant shall not directly or indirectly (i) provide any services in the Field
of Interest to any Person other than the Company, (ii) become an owner, partner, shareholder, consultant, agent, employee or co-venturer of any Person that has committed, or intends to commit, significant resources to the Field of Interest.
Notwithstanding the foregoing, the Consultant may purchase as a passive investment up to one percent (1%) of any class or series of outstanding voting securities of any Person that has committed significant resources to the Field of Interest if such
class or series is listed on a national or regional securities exchange or publicly traded in the “over-the-counter” market. 
 11. Nonsolicitation. During the term of this Agreement and for a period of one year after the termination of this Agreement, the Consultant shall not (i) solicit, encourage, or take any other
action which is intended to induce any employee of, or consultant to, the Company (or any other Person who may have been employed by, or may have been a consultant to, the Company during the term of this Agreement) to terminate his or her employment
or relationship with the Company in order to become employed by or otherwise perform services for any other Person or (ii) solicit, endeavor to entice away from the Company or otherwise interfere with the relationship of the Company with any
Person who is, or was within the then-most recent 12 month period, a client or customer of the Company. 
 12. Return of
Property. Upon termination of the Consultant’s engagement with the Company, or at any other time upon request of the Company, the Consultant shall return promptly any and all Confidential Information, including customer or prospective
customer lists, other customer or prospective customer information or related materials, computer programs, software, electronic data, specifications, drawings, blueprints, medical devices, samples, reproductions, sketches, notes, notebooks,
memoranda, reports, records, proposals, business plans, or copies of them, other documents or materials, tools, equipment, or other property belonging to the Company or its customers which the Consultant may then possess or have under his control.
The Consultant further agrees that upon termination of his engagement he shall not take with him any documents or data in any form or of any description containing or pertaining to Confidential Information or any Company Inventions. 

13. Miscellaneous. 
 (a) Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all other prior
agreements and understandings, both written and oral, between the parties with respect to such subject matter. 
 (b)
Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Agreement is not intended to confer upon any person other than the parties hereto any
rights or remedies hereunder, except as otherwise expressly provided herein and shall not be assignable by operation of law or otherwise. 
 (c) Amendments and Supplements. This Agreement may not be altered, changed or amended, except by an instrument in writing signed by the parties hereto. 

  
 - 5 -

 (d) No Waiver. The terms and conditions of this Agreement may be waived only by a
written instrument signed by the party waiving compliance. The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the
validity of this Agreement or any part hereof or the right of such party thereafter to enforce each and every such provision. No waiver of any breach of or non-compliance with this Agreement shall be held to be a waiver of any other or subsequent
breach or non-compliance. 
 (e) Governing Law; Jurisdiction. This Agreement shall be governed by, and construed and
enforced in accordance with, the substantive laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. All litigation arising from or relating to this Agreement shall be filed in, prosecuted before, and
resolved by any court of competent subject matter jurisdiction in Boston, Massachusetts. The Consultant consents to the jurisdiction of the courts located in Boston, Massachusetts over him, stipulates to the convenience, efficiency and fairness of
proceeding in such courts, and covenants not to allege or assert the inconvenience, inefficiency or unfairness of proceeding in such courts. 
 (f) Notice. All notices and other communications hereunder (other than Consulting Services, which shall be delivered in the manner specified in Section 1 and Schedule A) shall be in
writing and shall be deemed given if delivered by hand, sent by facsimile transmission with confirmation of receipt, sent via a reputable overnight courier service with confirmation of receipt requested, or mailed by registered or certified mail
(postage prepaid and return receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice), and shall be deemed given on the date on which delivered by hand or otherwise on
the date of receipt as confirmed: 
 To the Company: 
 BIND Biosciences, Inc. 
 1000 Winter Street 

Suite 3350 

Waltham, MA 02451 

Attention: President 
 To the Consultant: 
 Omid Farokhzad 

490 Beacon Street 

Chestnut Hill, MA 02476 
 (g) Remedies. The Consultant recognizes that money damages alone would not adequately compensate the Company in the event of breach by the Consultant of this Agreement, and the Consultant therefore
agrees that, in addition to all other remedies available to the Company at law, in equity or otherwise, the Company shall be entitled to injunctive relief for the enforcement hereof. All rights and remedies hereunder are cumulative and are in
addition to and not exclusive of any other rights and remedies available at law, in equity, by agreement or otherwise. 

  
 - 6 -

 (h) Survival; Validity. Notwithstanding the termination of the Consultant’s
relationship with the Company (whether pursuant to Section 4 or otherwise), the Consultant’s covenants and obligations set forth in Sections 6, 7, 9, 10, 11, 12 and 13 shall remain in effect and be fully enforceable in accordance with the
provisions thereof. In the event that any provision of this Agreement shall be determined to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities, it
shall be interpreted to extend only over the maximum period of time, geographic area or range of activities as to which it may be enforceable. If, after application of the preceding sentence, any provision of this Agreement shall be determined to be
invalid, illegal or otherwise unenforceable by a court of competent jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this
Section 13(h), any invalid, illegal or unenforceable provision of this Agreement shall be severable, and after any such severance, all other provisions hereof shall remain in full force and effect. 

(i) Construction. A reference to a Section or a Schedule shall mean a Section in or Schedule to this Agreement unless otherwise
expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which shall be considered as a whole. The words “include,”
“includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” Whenever the context may require, any pronouns used herein shall include
the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 (j) Certain Definitions. 
 “Cause” shall mean:
(i) Consultant’s dishonesty with respect to the Company; (ii) Consultant’s misconduct which materially and adversely reflects upon the business, affairs, operations, or reputation of the Company or upon Consultant’s ability
to perform his duties for the Company; (iii) Consultant’s failure to perform his duties and responsibilities for the Company, which failure continues for more than ten (1 0) days after the Company gives written notice to Consultant which
sets forth in reasonable detail the nature of such failure; (iv) Consultant’s negligent performance of his duties, which negligent performance continues for more than ten (1 0) days after the Company gives written notice to Consultant
which sets forth in reasonable detail the nature of such negligence; or (v) Consultant’s breach of any one or more of the material provisions of this Agreement, which breach continues for more than ten (1 0) days after the Company gives
written notice to Consultant which sets forth in reasonable detail the nature of such breach. 
 “Field of
Interest” shall mean PEG-PLGA nanoparticles functionalized with macromolecules for human therapeutic applications. (For the avoidance of doubt, PEG is an abbreviation of polyethylene glycol and PLGA is an abbreviation for poly
lactic-co-glycolic acid.) 

  
 - 7 -

 “Person” shall mean an individual, a corporation, an association, a
partnership, an estate, a trust and any other entity or organization. 
 (k) Counterparts. This Agreement may be executed
in one or more counterparts, all of which together shall constitute one and the same Agreement. Facsimile transmission of execution copies or signature pages for this Agreement shall be legal, valid and binding execution and delivery for all
purposes. 
 ***** 

  
 - 8 -

 IN WITNESS WHEREOF, the parties have caused this Consulting Agreement to be executed as an
agreement under seal as of the date first written above. 
  

			
	BIND BIOSCIENCES, INC.
		
	By :	 	/s/ Glenn Batchelder
	Name:	 	CEO
	Title:	 	Glenn Batchelder
	
	CONSULTANT:
	
	/s/ Omid Farokhzad
	Omid Farokhzad

  
 - 9 -

 Schedule A 
 1. Description of Consulting Services. 
 The Consultant shall provide
consulting services to the Company as may be mutually determined by the Company and Consultant from time to time. In determining the times and locations for the performance of such services, due consideration shall be given to Consultant’s
commitments to Harvard, Brigham or any future employer of Consultant. 
 2. Compensation. 

2.1 The Company shall pay Consultant a periodic consulting fee payable quarterly in arrears on the first day of February, May, August and
November of each year during the term of this Agreement and all renewal terms of this Agreement. Such consulting fee shall initially be $0.00, but shall increase upon the occurrence of the following events: (i) to $25,000 per 365-day period on
and after the Initial Milestone Date (as defined below) and continuing until the Second Milestone Date (as defined below); (ii) to $50,000 per 365-day period on and after the Second Milestone Date and continuing until the Third Milestone Date
(as defined below); (iii) to $75,000 per 365-day period on and after the Third Milestone Date and continuing until the Fourth Milestone Date (as defined below); and (iv) to $100,000 per 365-day period on and after the Fourth Milestone
Date. 
 As used herein, the term “Initial Milestone Date” shall mean the date upon which the cumulative Cash
Flow (as defined below) received by the Company shall be greater than $2,500,000; the term “Second Milestone Date” shall mean the date upon which the cumulative Cash Flow received by the Company shall be greater than $10,000,000;
the term “Third Milestone Date” shall mean the date upon which the cumulative Cash Flow received by the Company shall be greater than $25,000,000; and the term “Fourth Milestone Date” shall mean the earliest to
occur of (i) the date upon which the cumulative Cash Flow received by the Company shall be greater than $50,000,000, (ii) the consummation by the Company of an Initial Public Offering (as defined below) or (iii) the sale of the
Company in a merger or consolidation in which the Company is not the surviving corporation or in which the Company is the surviving corporation but becomes a wholly-owned subsidiary of another corporation, or involving the sale of substantially all
of the Company’s assets. 
 The term “Cash Flow” shall include all funds received by the Company (other
than funds which must be repaid), including, without limitation, the proceeds of the sale of equity securities by the Company and the committed proceeds for equity and research funding in connection with a strategic alliance or corporate partnering
transaction with a third party in the Field of Interest. 
 The term “Initial Public Offering” shall mean a
firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of the Company’s Common Stock to the public, for the account of the Company,
at a public offering price of at least $3.00 per share, with such amount to be appropriately adjusted to take account of any stock split, stock dividend, subdivision, combination of shares, or the like, and having an aggregate offering price to the
public of not less than $30,000,000. 

  
 - 10 -

 2.2 Consultant shall be reimbursed for all reasonable, appropriate or necessary travel and
other out-of-pocket expenses incurred in the performance of his duties hereunder upon submission and approval of written statements and bills in accordance with the then regular reimbursement procedures of the Company. 

  
 - 11 -

 Addendum to Consulting Agreement 

The Company acknowledges that Consultant’s primary employment responsibility is to Harvard Medical School and Harvard University
(together, “HMS”) and that Consultant’s obligations under HMS policies take priority over any obligations that Consultant may have to the Company by reason of this Agreement. 

The Company acknowledges that Consultant’s activities may be further bound by the policies of Governmental agencies (e.g. the
National Institutes of Health) or funding agencies (e.g., the Howard Hughes Medical Institute or the Juvenile Diabetes Foundation) as applicable, including policies relating to consulting and conflicts of interest, and that such policies may take
priority over any obligations that Consultant may have to the Company by reason of this Agreement. 
 The parties understand and
agree that it is Consultant’s responsibility to ensure that Consultant’s services to the Company do not employ proprietary information of HMS nor make substantial use of HMS’s time or resources nor involve HMS students, employees,
post-doctoral trainees or any other HMS personnel other than the Consultant. 
 Subject to obligations to protect the
Company’s proprietary or confidential information, Consultant’s services may not restrict or hinder his/her ability to conduct current or foreseeable research or teaching assignments with HMS, nor limit Consultant’s ability to publish
work generated at or on the behalf of HMS, nor infringe on Consultant’s academic freedom. 
 The Company will have no
rights by reason of the Agreement in any intellectual property whatsoever, whether or not patentable or copyrightable, generated wholly or in part as a result of Consultant’s activities as an employee of HMS or using the resources or
proprietary information of HMS. 
 The Company further acknowledges that Consultant will serve as a consultant in the capacity
of an individual, and not as an agent, employee or representative of HMS. Any confidential or other information provided to Consultant by Company will be deemed received only by Consultant as an individual and not by HMS, and any obligations
pertaining thereto will apply only to the Consultant and not HMS. 
 The name of HMS or Harvard or its affiliates may not be
used in connection with Consultant’s services, other than in affiliation as his employer, without written permission from HMS. 
  

									
	BIND Biosciences, Inc.	 		 	CONSULTANT
				
	By:	 	 /s/ Glenn Batchelder
	 		 	 /s/ Omid Farokhzad

	Name:	 	Glenn Batchelder	 		 	Omid Farokhzad
	Title:	 	CEO	 		 		 	
	Date:	 	7/12, 2007	 		 	Date:	 	7/12/07, 2007

					
	

	  	BIND Biosciences, Inc.	  	www.bindbio.com
		  	64 Sidney Street	  	p 617.491.3400
		  	Cambridge, MA 02139	  	f 617.491.0351

 June 11, 2010 
 Omid Farokhzad 
 490 Beacon Street 
 Chestnut Hill, Massachusetts 03476 
  

	Re:	Modifications to Consulting Agreement 

Dear Omid: 
 The purpose of
this letter agreement (this “Amendment”) is to amend certain provisions to your consulting agreement with BIND Biosciences, Inc. (the “Company”) dated as of October 31, 2006 (your “Original Consulting
Agreement”). 
 Schedule A to your Original Consulting Agreement provides that your periodic consulting fee will
increase periodically upon the occurrence of certain triggering events. After discussion, we have agreed that the increase scheduled to occur at the Fourth Milestone Date, as defined in the Original Consulting Agreement, should take place as of
today’s date. Accordingly, the defined term “Fourth Milestone Date” is hereby amended as follows: 
 The term
“Fourth Milestone Date” shall mean June 11, 2010. 
 Except as expressly amended by this Amendment, your
Original Consulting Agreement remains in full force and affect and otherwise unchanged. The Original Consulting Agreement shall, together with this Amendment, be read and construed as a single document. Please indicate your agreement to the
Amendment by signing below. 
  

			
	Very truly yours,
	
	BIND BIOSCIENCES, INC.
		
	By:	 	/s/ Scott Minick
		 	  
 Scott
Minick

		 	President and Chief Executive Officer

  

	
	Acknowledged and agreed by:
	
	 /s/ Omid Farokhzad

	Omid Farokhzad

					
	 

	  	                 BIND Therapeutics,
Inc.
                 325 Vassar Street

                Cambridge, MA 02139
	  	 www.bindtherapeutics.com
 phone 617.491.3400
 fax 617.491.0351

 August 28, 2013 
 Omid Farokhzad 
 490 Beacon Street 
 Chestnut Hill, MA 03476 
  

	 	Re:	Additional Modifications to Consulting Agreement 

 Dear Omid: 
 Reference is made to that certain Amended and Restated Consulting
Agreement, dated as of July 12, 2007, by and between BIND Therapeutics, Inc., formerly known as BIND Biosciences, Inc. (the “Company”), and you (the “Initial Agreement”) as modified by that certain letter re:
Modifications to Consulting Agreement, dated June 11, 2010 by and between the Company and you (the “Modification,” and together with the Initial Agreement, the “Consulting Agreement”). 

Effective upon the date of the closing of the initial public offering of the Company’s common stock (the “Effective
Date”), Schedule A to the Initial Agreement, as modified by the Modification, is hereby amended and restated in its entirety to read as follows: 
 Schedule A 
 1. Description of Consulting Services. 

The Consultant shall participate as a member of the Company’s Scientific Advisory Board and shall provide such other consulting
services to the Company as may be mutually determined by the Company and Consultant from time to time. In determining the times and locations for the performance of such services, due consideration shall be given to Consultant’s commitments to
Harvard, Brigham or any future employer of Consultant. 
 2. Compensation. 

2.1 The Company shall pay Consultant a periodic consulting fee payable quarterly in arrears on the first day of February, May, August and
November of each year during the term of this Agreement and all renewal terms of this Agreement. Such consulting fee shall be $22,500 per quarter, and shall be pro-rated for any partial period based on the number of days elapsed during the quarter.

 2.2 Consultant shall be reimbursed for all reasonable, appropriate or necessary travel and
other out-of-pocket expenses incurred in the performance of his duties hereunder upon submission and approval of written statements and bills in accordance with the then regular reimbursement procedures of the Company. 

You agree that, from and after the Effective Date, the compensation set forth in this letter above, together with any compensation that you may be
entitled to receive under the Company’s Non-Employee Director Compensation Program to be effective upon the closing of the initial public offering of the Company’s common stock, shall represent full compensation for your service to the
Company as a member of the board of directors, as a consultant or otherwise and that, from and after the Effective Date, except as may be provided in such Non-Employee Director Compensation Program or otherwise agreed between you and the Company in
writing, you shall not be entitled to any additional board or consulting fees from the Company. 
 Except as expressly set forth
in this letter, the Consulting Agreement shall remain unchanged and shall continue in full force and effect according to their respective terms. 
  

			
	Sincerely,
	
	BIND THERAPEUTICS, INC.
		
	By:	 	/s/ Scott Minick
	Name:	 	Scott Minick
	Title:	 	President & Chief Executive Officer

  

	
	Acknowledged and Agreed:
	
	/s/ Omid Farokhzad
	Omid Farokhzad

  
 2EX-10.7

 Exhibit 10.7 

 
 

 
 January 11, 2010 
 Mr. Scott Minick 
 69 Wellington Avenue 

San Anselmo, CA 94960 
  

	Re:	Employment Offer Letter 

 Dear Scott:

 I am pleased to provide you with the terms and conditions of your anticipated employment by BIND Biosciences, Inc. (the
“Company” or “BIND”). The following sets forth the terms and conditions of our offer of employment to you. 

1. Position. 

(a) You will be the President and Chief Executive Officer (“CEO”) of the Company, reporting to the Company’s board
of directors (“Board”). You will be expected to devote your full business time and your reasonable professional efforts to the performance of your duties and responsibilities for the Company and to abide by all Company policies and
procedures, as in effect from time to time. You will be expected to perform the duties of your position and such other duties as reasonably may be assigned to you from time to time by the Board. The Board will review your performance on an annual
basis. 
 (b) You will serve as a director on the Board for so long as you serve as the CEO or until your earlier death,
resignation or removal. In accordance with the Second Amended and Restated Voting Agreement dated as of July 22, 2009, among the Company and certain of its stockholders, as the same may be amended from time to time, you will occupy the position
designated for the CEO. Subject to the second sentence of Section 1(a) and to prior approval of the Board (which approval shall not be unreasonably withheld), you may serve as a director of up to two companies other than BIND as well as a role
as an affiliate of ARCH Venture Partners. The Board acknowledges and approves your current board seats at Sorbent Therapeutics and Chiasma and that you will serve as the point of contact for ARCH Venture Partners to the Company under this
Section 1b. 
 2. Starting Date/Nature of Relationship. If you accept this offer, your employment with the Company will begin
on January 11, 2010 (the “Start Date”). No provision of this letter shall be construed to create a promise of employment for any specific period of time. Your employment with the Company is at-will employment, which may be
terminated by you or the Company at any time for any reason. 

 January 11, 2010 
  Page
 2
 of 7 
  

 3. Compensation and Benefits. 

(a) The Company will pay you a base salary at the rate of $395,000 per year, payable in accordance with the regular payroll practices of
the Company, less any legally required deductions for federal and state taxes and the like, or other deductions which you authorize. 
 (b) In addition to your annual base salary, the Company will allow you non-exclusive use of company leased accommodations close to the Company offices for 1 year. The Company will also reimburse your
actual relocation expenses, not to exceed a total sum of $75,000, if in the first year or $50,000 if in the second year if in the second or later years, subject to your production of receipts for those expenses. In the event that you terminate your
employment for any reason other than Good Reason (as defined in Section 3e) within six months after the Start Date, then you shall promptly refund to the Company 50% of all amounts paid to you pursuant to this Section 3(b). The Company
will reimburse you for any income taxes incurred as a result of these relocation payments. The Company, through the Board’s Compensation Committee, agrees to consider changes to this relocation package at your request in light of future facts
and circumstances. 
 (c) Promptly after the Start Date, the Company shall sell you [1,158,069] shares (the
“Shares”) of the Company’s common stock, $0.0001 par value per Share (“Common Stock”), at a price of $0.46 per Share. The purchase and sale of Shares shall be made pursuant to the Company’s 2006 Stock
Incentive Plan and shall be governed by a Restricted Stock Purchase Agreement, substantially in the form of Exhibit 3(c) (the “Restricted Stock Purchase Agreement”), which shall contain, among other things, a right of the
Company to repurchase unvested Shares under certain circumstances. The Shares will be subject to vesting requirements such that: 8.33% of the Shares shall be vested on the Start Date; 22.91% of the Shares shall vest on January 11, 2011; and
1.91% of the Shares shall vest on the 11th day of each
month thereafter; for a total four-year vesting period, with accelerated vesting under certain circumstances, all as set forth in greater detail in the Restricted Stock Purchase Agreement. You may be eligible to receive additional stock options as
determined by the Compensations Committee and Board to ensure that your equity ownership in the Company remains competitive with CEO’s of comparable biotechnology companies. 

(d) To facilitate your purchase of the Shares, the Company shall make a full-recourse loan to you in the principal amount of $532,712.
The loan shall be evidenced by a promissory note from you to the Company in the form of Exhibit 3(d). The loan shall bear interest at the rate of 2.45% per annum and shall mature and be repaid to the Company on the earliest to occur of:
(i) an initial public offering of the Company; (ii) within 30 days after the voluntary termination of your employment with the Company without Good Reason, or involuntary termination with Cause; (iii) six months after other
termination of employment or (iv) January 11, 2018. 
 (e) In the event that your employment were to be terminated by
the Company without “Cause” or you resign your employment for “Good Reason” (as both terms are defined below), you will receive a severance benefit of up to twelve months of base salary continuation and up to twelve months of
reimbursement of COBRA premiums for medical insurance coverage, so long as you are eligible to elect COBRA benefits. In addition, you will receive vesting acceleration of twelve months from the date of termination. The Company’s severance
obligations may be conditioned upon your execution and delivery to the Company of a reasonable release of claims. 

 January 11, 2010 
  Page
 3
 of 7 
  

 “Cause” for termination shall mean: (i) commission of, or indictment or conviction
for, any felony or any crime involving moral turpitude; (ii) participation in any fraud against the Company; (iii) your substantial failure to perform (other than by reason of disability), or gross negligence in the performance of, your
duties and responsibilities to the Company or any of its affiliates; (iv) other conduct by you that is or could reasonably anticipated to be harmful to the business, interests or reputation of the Company or any of its affiliates; or
(v) your breach of any material provision of any agreement between you and the Company including this agreement and the Nondisclosure Agreement (as defined in Section 5). 
 “Good Reason” shall mean any termination of your employment by you immediately following any of the following: (i) a change in your principal work location despite your stated
disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company business shall not be deemed a change in principal work location); (ii) a reduction by
the Company in your salary or benefits (provided, that if the Board has determined that it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if
(a) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar seniority and (b) the reduction does not reduce the salary and benefits by more than 20% below the level
then in effect); or (iii) a reduction by the Company in your duties, position, title, or responsibilities (unless such reduction occurs after a Change of Control, as defined below, in which case a mere change in title or reporting
responsibilities shall not constitute Good Reason). 
 “Change of Control” means the closing of (i) a sale of all or
substantially all of the assets of the Company, or (ii) a stock tender or a merger, consolidation or similar event pursuant to a transaction or series of related transactions in which a third party acquires more than fifty percent (50%) of
the equity voting securities of the Company outstanding immediately prior to the consummation of such transaction or series of transactions, and the shareholders of the Company do not retain a majority of the equity voting securities of the
surviving entity, other than (x) a merger, conversion or other transaction the principal goal of which is to change the jurisdiction of incorporation of the Company, or (y) an equity security financing for the account of the Company in
which capital stock of the Company is sold to one or more institutional investors. 
 (f) You will be eligible to participate in
all employee benefit plans made generally available by the Company from time to time to its employees, subject to plan terms and generally applicable Company policies. These benefits, of course, may be modified or changed from time to time at the
sole discretion of the Board, and the provision of such benefits to you in no way changes or impacts your status as an at-will employee. 
 (g) You will be entitled to earn vacation in accordance with the Company’s policies from time to time in effect, in addition to holidays observed by the Company, subject to a minimum entitlement of
four weeks vacation. Vacation may be taken subject to the business needs of the Company, and otherwise shall be subject to the policies of the Company, as in effect from time to time. 

(h) The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of your duties
and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as it may specify from time to time. 

 January 11, 2010 
  Page
 4
 of 7 
  

 4. Before You Start. Your employment with the Company is conditioned on your eligibility
to work in the United States. On or before the Start Date, you must complete an I-9 Form and provide the Company with any of the accepted forms of identification specified on the I-9 Form. A copy of an I-9 Form is enclosed for your information.
Please bring the appropriate documents listed on that form with you when you report to work. 
 5. Confidentiality and Other
Obligations. The Company considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. Given the confidential nature of various aspects of our business, you may not discuss the fact
or terms of this offer or any employment discussions with anyone other than a member of the Board and members of your immediate family (and, if relevant, your financial advisor or lawyer). In addition, as a condition of this offer of employment, you
are required to carefully review and then sign the Employee Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement (the “Non-Disclosure Agreement”) enclosed with this letter. 

6. Legal Expenses. The Company shall reimburse you the reasonable fees and expenses of your legal counsel incurred in connection with this
offer of employment and all related documents and transactions contemplated thereby, up to a maximum payment for such fees and expenses of $7,500. 
 7. Conflicting Agreements. You hereby represent and warrant to the Company that your signing of this agreement and the performance of your obligations under it will not breach or be in
conflict with any other agreement to which you are a party or are bound, and that you are not now subject to any covenants against competition or similar covenants or any court orders that could affect the performance of your obligations under this
Agreement. You agree that you will not disclose to or use on behalf of the Company any proprietary information of a third party without that party’s consent. 
 8. Miscellaneous. This letter and the Non-Disclosure Agreement constitute our entire offer regarding the terms and conditions of your prospective employment with the Company. It supersedes
any prior proposals, agreements, or other promises or statements (whether oral or written) regarding the offered terms of employment. The terms of your employment shall be governed by the laws of The Commonwealth of Massachusetts, without regard to
its principles of conflicts of laws. 
 [Signature page follows] 

 January 11, 2010 
  Page
 5
 of 7 
  

 If the terms of this offer are acceptable to you, please sign this letter in the place provided and
return it to me no later than January 8, 2010. Your signature on the copy of this letter and your delivery of the signed copy to the Company will evidence your agreement with the terms and conditions set forth herein. 

We are excited to offer you the opportunity to lead the BIND team as its CEO, and we look forward to working with you in this new capacity. We are
confident that you will make a major contribution to our unique and exciting enterprise. 
  

	
	Sincerely,
	
	 /s/ Andrea Franz

	Andrea Franz
	Chief Financial Officer

 Accepted and Agreed as of January 11, 2010 

 

	
	 /s/ Scott Minick

	Scott Minick

 January 11, 2010 
  Page
 6
 of 7 
  

 Exhibit 3(c) 
 Restricted Stock Purchase Agreement 

 RESTRICTED STOCK PURCHASE AGREEMENT 

(Scott Minick) 

This Restricted Stock Purchase Agreement (this “Agreement”) dated as of January 11, 2010 (the “Effective
Date”), is made by and between BIND Biosciences, Inc., a Delaware corporation (the “Company”), and Scott Minick (“Purchaser”). 
 WHEREAS, the Company and Purchaser have entered into that certain employment offer letter agreement of even date herewith (the “Employment Agreement”), pursuant to which Purchaser shall
serve as an employee and officer of the Company; and 
 WHEREAS, the Company desires to sell to Purchaser, and Purchaser desires
to purchase from the Company, 1,158,706 shares of the Company’s Common Stock, $0.0001 par value per share (“Common Stock”). 
 NOW, THEREFORE, in consideration of the premises and the promises set forth herein, and for other good and valuable consideration, the parties agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 

Act: The Securities Act of 1933, as amended. 
 Change of Control: The closing of (i) a sale of all or substantially all of the assets of the Company, or (ii) a stock tender or a merger, consolidation or similar event pursuant to a
transaction or series of related transactions in which a third party acquires more than fifty percent (50%) of the equity voting securities of the Company outstanding immediately prior to the consummation of such transaction or series of
transactions, and the shareholders of the Company do not retain a majority of the equity voting securities of the surviving entity, other than (x) a merger, conversion or other transaction the principal goal of which is to change the
jurisdiction of incorporation of the Company, or (y) an equity security financing for the account of the Company in which capital stock of the Company is sold to one or more institutional investors. 

Good Reason: shall mean any termination of Purchaser’s employment by Purchaser immediately following any of the following:
(i) a change in Purchaser’s principal work location despite Purchaser’s stated disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company
business shall not be deemed a change in principal work location); (ii) a reduction by the Company in Purchaser’s salary or benefits (provided, that if the Board has determined that it is in the best interests of the Company to reduce
compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if (a) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar
seniority and (b) the reduction does not reduce the salary and benefits by more than 20% below the level then in effect); or (iii) a reduction by the Company in Purchaser’s duties, position, title, or responsibilities (unless such
reduction occurs after a Change of Control in which case a mere change in title or reporting responsibilities shall not constitute Good Reason). 

 Service: Service to the Company in the role of a director, officer, employee or
consultant of the Company. 
 Shares: The shares of Common Stock issued to Purchaser hereunder and any other securities
of the Company which may be issued in exchange for or in respect of such shares of Common Stock, whether by way of stock split, stock dividend, combination of shares, reclassification, recapitalization, reorganization or any other means. 

Unvested Shares: Any Shares that are not Vested Shares. 
 Vested: Released from the Company’s Repurchase Option (as defined in Section 5(a)). 
 Vested Shares: Any Shares that have Vested in accordance with Section 5(b). 
 2. Purchase and Sale of Shares. Pursuant to the terms and conditions set forth in this Agreement, the Company hereby sells to Purchaser, and Purchaser hereby purchases from the Company, 1,158,706
shares of the Company’s Common Stock for a purchase price per share of $0.46, and an aggregate purchase price of $533,005. The Company acknowledges receipt from Purchaser of a full-recourse promissory note in the principal amount of $533,005,
as full consideration for such purchase price. Purchaser and the Company hereby agree that the fair market value of the Shares on the date hereof is $0.46 per share. 
 3. Representations of Purchaser. Purchaser understands that the Shares are not registered under the Act, and represents to the Company, and agrees that the Company is entitled to rely on such
representations, as follows: 
 (a) Purchaser understands that the Shares have not been registered under the Act, or registered
or qualified under the securities or “Blue Sky” laws of any jurisdiction, and are being sold pursuant to exemptions contained in the Act and exemptions contained in other applicable securities or “Blue Sky” laws. Purchaser
understands further that the Company’s reliance on these exemptions is based in part on the representations made by Purchaser in this Agreement. In this connection, Purchaser represents and warrants that the offer and sale of the Shares were
made solely in Massachusetts. 
 (b) Purchaser understands the term “accredited investor” as used in Regulation D
promulgated under the Act and represents and warrants to the Company that he is an “accredited investor” for purposes of acquiring the Shares. The nature and amount of Purchaser’s investment in the Shares is consistent with
Purchaser’s investment objectives, abilities and resources. Purchaser understands that the Shares are an illiquid investment, which will not become freely transferable by reason of any “change of circumstances” whatever. Purchaser has
adequate means of providing for Purchaser’s current needs and possible contingencies and has no need for liquidity in Purchaser’s investment. 
 (c) Purchaser is acquiring the Shares for Purchaser’s own account for investment, and not for, with a view to, or in connection with the resale or distribution thereof. Purchaser has no present
intention to sell, hypothecate, distribute or otherwise transfer the Shares or any portion thereof or any interest therein. 

  
 2 

 (d) Purchaser understands that the Shares will constitute “restricted securities”
within the meaning of Rule 144 promulgated under the Act and that, as such, the Shares must be held indefinitely unless they are subsequently registered under the Act or unless an exemption from the registration requirements thereof is available.
Purchaser has been advised that Rule 144, which permits the resale, subject to various terms and conditions, of small amounts of such “restricted securities” after they have been held for one year, does not now apply to the Company,
because the Company is not now required to file, and does not file, current reports under the Securities Exchange Act of 1934, and because information concerning the Company substantially equivalent to that which would be available if the Company
were required to file such reports is not now publicly available. The Company may become a reporting entity at some future date, but no assurance can be given that it will do so. 

(e) In connection with Purchaser’s acquisition of the Shares, Purchaser accepts the condition that the Company may maintain
“stop transfer” orders with respect to the Shares and that each certificate or other document evidencing the Shares will bear conspicuous legends in substantially the form set forth in Section 7 of this Agreement. 

(f) Purchaser has consulted Purchaser’s attorney or accountant with respect to Purchaser’s purchase of the Shares. Purchaser
has fully investigated the Company and its business and financial condition and has knowledge of the Company’s current activities. Purchaser acknowledges that the Company has granted Purchaser and Purchaser’s attorney or accountant access
to all information about the Company which they have requested and has offered each of them access to all further information which they deemed relevant to an investment decision with respect to the Shares. Purchaser and Purchaser’s attorney or
accountant have had the opportunity to ask questions of, and receive answers from, representatives of the Company concerning such information and the Company’s financial condition and prospects. 

4. Restrictions on Transfer. The following restrictions on transfer of the Shares shall apply: 

(a) Securities Laws. Except for purchases of Unvested Shares by the Company as contemplated by Section 5, no Shares, nor any
interest therein, may be sold, assigned, pledged or otherwise transferred at any time or under any circumstances unless (i) the Shares proposed to be transferred have been registered under the Act and qualified under applicable state securities
laws, or (ii) the Company has received, or agreed to waive, an opinion of counsel acceptable to the Company to the effect that such transfer may be effected without registration under the Act or qualification under the securities laws of
relevant states and the proposed transferee has made such representations and agreements as the Company shall require to assure compliance with the Act and such laws. 
 (b) Termination of Repurchase Option. Except for purchases of Unvested Shares by the Company as contemplated by Section 5, no Shares, nor any interest therein, may be sold, assigned, pledged
or otherwise transferred until the Repurchase Option shall have terminated with respect to such Shares. 

  
 3 

 (c) Right of First Refusal and Co-Sale. As a condition precedent to the
Company’s issuance and sale of the Shares, Purchaser shall enter into that certain Second Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of July 22, 2009, among the Company and certain of its stockholders (as
the same may be amended from time to time, the “ROFR and Co-Sale Agreement”) and assume the duties of, and be bound by the restrictions applicable to, a Restricted Stockholder. 

(d) Voting Agreement. As a condition precedent to the Company’s issuance and sale of the Shares, Purchaser shall enter into
that certain Second Amended and Restated Voting Agreement dated as of July 22, 2009, among the Company and certain of its stockholders (as the same may be amended from time to time, the “Voting Agreement”) and assume the duties
of, and be bound by the restrictions applicable to, an Executive Officer. 
 (e) Permitted Transfers. Any portion or all
of the Vested Shares may, without compliance with the provisions of Section 4(b), be transferred by Purchaser to a member of his immediate family or to a family partnership or family trust, or on Purchaser’s death may be transferred to
Purchaser’s estate or to those entitled to a distribution of the Vested Shares under the laws of descent and distribution, provided that Shares that are so transferred shall remain subject to this Section 4 and as a condition to any
transfer Purchaser shall obtain a written agreement from the transferee by which the transferee agrees to be bound by this Section 4. 
 (f) Remedies. No sale, assignment, pledge or other transfer of Shares shall be effective or given effect on the books of the Company unless all of the applicable provisions of this Section 4
have been duly complied with. If any transfer of Shares is made or attempted in violation of such restrictions, or if Shares are not offered to the Company as required hereby, the Company shall have the right to purchase such Shares from the
purported owner thereof or his transferee at any time before or after the transfer, as herein provided. In addition to any other legal or equitable remedies which it may have, the Company may enforce its rights by actions for specific performance
(to the extent permitted by law) and may refuse to recognize any transferee as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights, until all applicable provisions hereof have been
complied with. 
 (g) Lock-Up. Purchaser agrees that for a period of up to 180 days from the effective date of any
registration of securities of the Company (upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities), he will not sell, make any short sale or loan of, grant any option for the purchase of,
or otherwise dispose of any Shares held by him without the prior written consent of the Company or such underwriters, as the case may be. 
 5. Repurchase of Unvested Shares. 
 (a) Repurchase Option.

 (i) In the event of the termination of Purchaser’s Service by Purchaser or the Company for any reason, with or without
cause, the Company shall upon the date of such termination (the “Termination Date”) have an irrevocable, exclusive option (the “Repurchase Option”) for a period of 90 days from such date to repurchase all or any
portion of the Unvested 

  
 4 

 
Shares at the per share repurchase price of $0.46 per share, appropriately adjusted in the event of a stock dividend, stock split, recapitalization, combination of shares or similar event
occurring subsequent to the date of this Agreement. 
 (ii) Unless the Company notifies Purchaser within 90 days from the date
of termination of Purchaser’s Service that it does not intend to exercise its Repurchase Option with respect to some or all of the Unvested Shares, the Repurchase Option shall be deemed automatically exercised by the Company as of the 90th day
following such termination, provided, that the Company may notify Purchaser that it is exercising its Repurchase Option as of a date prior to such 90th day. Unless Purchaser is otherwise notified by the Company pursuant to the preceding
sentence that the Company does not intend to exercise its Repurchase Option as to some or all of the Unvested Shares to which it applies at the time of termination, execution of this Agreement by Purchaser constitutes written notice to Purchaser of
the Company’s intention to exercise its Repurchase Option with respect to all Unvested Shares to which such Repurchase Option applies. The Company, at its choice, may satisfy its payment obligation to Purchaser with respect to exercise of the
Repurchase Option by any of (1) delivering a check to Purchaser in the amount of the purchase price for the Unvested Shares being repurchased, (2) in the event Purchaser is indebted to the Company, canceling an amount of such indebtedness
equal to the purchase price for the Unvested Shares being repurchased and (3) by a combination of (1) and (2) so that the combined payment and cancellation of indebtedness equals such purchase price. The Company shall use good faith
efforts to satisfy its payment obligation to Purchaser within 15 days after Company’s notice of exercise of the Repurchase Option (or deemed exercise), and that if such payment is not effective within such 15 days from such date, the amount of
the Company’s unsatisfied payment obligation shall bear interest at a rate of nine percent (9%) per annum until the Company has satisfied its payment obligation under this Section 5(a)(ii). In the event of any deemed automatic
exercise of the Repurchase Option pursuant to this Section 5(a)(ii) at such time as Purchaser is indebted to the Company, the portion of such indebtedness equal to the purchase price of the Unvested Shares being repurchased shall be deemed
automatically canceled as of the date of Company’s notice of exercise of the Repurchase Option (or deemed exercise). As a result of any repurchase of Unvested Shares pursuant to this Section 5(a), the Company shall become the legal and
beneficial owner of the Unvested Shares being repurchased and shall have all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the number of Unvested Shares being repurchased by the
Company, without further action by Purchaser. 
 (b) Vesting. 

(i) The Shares will become Vested as follows: 
 (1) 8.33% of the Shares shall vest on the Effective Date; 
 (2) An additional
22.91% of the Shares shall vest on January 11, 2011; and 

	

  
 5 

 (3) An additional 1.91% of the Shares shall vest on the 11th day of each month thereafter,
so that the Shares shall be fully Vested on the fourth anniversary of the Effective Date; 
 provided, however, that the
vesting of Shares on any such vesting date shall be conditioned upon Purchaser’s continuing Service to the Company from the date hereof through such vesting date. 
 (ii) Notwithstanding Section 5(b)(i), all Shares shall be deemed to have Vested after both of the following two conditions have been satisfied (A) a Change of Control, and (B) the
termination of Purchaser’s Service by the Company (or its successor, as the case may be) after such Change of Control or Resignation For Good Reason after such Change of Control. 

(iii) Notwithstanding Section 5(b)(i) and 5(b)(ii) an additional 22.92% of the Shares shall be deemed to have Vested if the
Purchaser is terminated without Cause or if Purchaser shall resign for Good Reason. If the aggregate of unvested Shares remaining is less than 22.92% of the Shares, then all Shares shall be deemed Vested if the Purchaser is terminated without Cause
or resigns for Good Reason. 
 6. Custody of Certificates. In order to facilitate the exercise of the Repurchase Option,
the Company or its counsel shall hold all certificates representing Unvested Shares, together with an adequate number of undated and otherwise blank stock powers executed by Purchaser. The Company shall have the right to cause transfers of Unvested
Shares to be effected pursuant to Section 4. After any Shares become Vested Shares, the Company shall, upon request of Purchaser, deliver to Purchaser a certificate or certificates representing such Vested Shares. After the Company sends
Purchaser a notice that it does not intend to exercise its Repurchase Option as to certain Unvested Shares, the Company shall, upon request of Purchaser, deliver to Purchaser a certificate or certificates representing such Unvested Shares.

 7. Legends. Each certificate representing Shares shall prominently bear legends in substantially the following forms:

 The securities represented by this certificate have been acquired for investment and have not been registered under the
Securities Act of 1933. Such securities may not be sold, transferred, pledged or hypothecated unless the registration provisions of said Act have been complied with or unless the Corporation has received an opinion of counsel reasonably satisfactory
to the Corporation that such registration is not required. 
 The securities represented by this certificate have been acquired
for investment and have not been registered or qualified under the securities or “Blue Sky” laws of any jurisdiction. Such securities may not be sold, transferred, pledged or hypothecated unless the registration, qualification and filing
requirements of all applicable jurisdictions have been satisfied or the Corporation has received an opinion of counsel reasonably satisfactory to the Corporation that the proposed transaction will be exempt from registration, qualification, and
filings in all such jurisdictions. 
 The Corporation is authorized to issue more than one class of stock. The powers,
designations, preferences and relative participating, optional or other special rights, and 

  
 6 

 
the qualifications, limitations or restrictions of such preferences and/or rights of each class of stock or series of any class are set forth in the Certificate of Incorporation of the
Corporation. The Corporation will furnish a copy of the Certificate of Incorporation of the Corporation to the holder hereof without charge upon written request. 
 The securities represented by this certificate are subject to restrictions on transfer and repurchase rights pursuant to the terms of a Restricted Stock Purchase Agreement, as amended from time to time,
between the owner of this certificate and the Corporation. The Corporation will furnish a copy of this agreement to the holder hereof without charge upon written request. 
 8. Miscellaneous. 
 (a) Entire Agreement. This Agreement constitutes
the entire agreement between the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written or oral, relating to such subject matter. 

(b) Amendments. Neither this Agreement nor any provision hereof may be changed or modified except by an agreement in writing
executed by Purchaser and on behalf of the Company. 
 (c) Binding Effect of the Agreement. This Agreement shall inure to
the benefit of, and be binding upon, the Company, Purchaser and their respective estates, heirs, executors, transferees, successors, assigns and legal representatives. 
 (d) Provisions Severable. In the event that any one or more of the provisions contained herein shall, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such
invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and all other provisions shall remain in full force and effect. If any of the provisions of this Agreement is held to be excessively broad, it shall
be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law. 
 (e)
Notices. All notices under this Agreement shall be effective (i) upon personal or facsimile delivery, (ii) two business days after deposit in the United States mail as registered or certified mail postage fully prepaid, or
(iii) one business day after pickup by any overnight commercial courier service, in each case sent or addressed to the Company at its principal office or to Purchaser at his record address as carried in the stock records of the Company, as the
case may be, or at such other address as either may from time to time designate in writing to the other. 
 (f)
Construction. A reference to a Section shall mean a Section of this Agreement unless otherwise expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this
Agreement which shall be considered as a whole. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without
limitation.” Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 

  
 7 

 (g) No Employment or Consulting Agreement. This Agreement shall not be construed as
an agreement by the Company to employ or engage Purchaser, nor is the Company obligated to employ or engage Purchaser by reason of this Agreement or the issuance of the Shares to Purchaser. 

(h) Section 83(b) Election. Purchaser will furnish to the Company a copy of any election made by Purchaser under
Section 83(b) of the Internal Revenue Code of 1986, as amended, with respect to his acquisition of the Shares. 
 (i)
Applicable Law. This Agreement shall be construed and enforced in accordance with the laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. Purchaser consents to jurisdiction and venue in any state
or federal court in The Commonwealth of Massachusetts for the purposes of any action relating to or arising out of this Agreement or any breach or alleged breach hereof, and to service of process in any such action by certified or registered mail,
return receipt requested. 
 (j) Disposition of Shares; Purchase by Nominee or Designee. Any Shares that the Company
elects to purchase hereunder may be disposed of by it in such manner as it deems appropriate with or without restrictions on the transfer thereof, and the Company may require their transfer to a nominee or designee as part of any purchase of Shares
from Purchaser. 
 (k) Withholding Taxes. Purchaser acknowledges and agrees that the Company has the right to deduct from
payments of any kind otherwise due to Purchaser any federal, state or local taxes of any kind required by law to be withheld with respect to the purchase of the Shares by Purchaser. 

[remainder of page intentionally left blank] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Purchase
Agreement as of the date first above written. 
  

			
	BIND BIOSCIENCES, INC.
		
	By:	 	  

	Name:	 	Andrea Franz
	Title:	 	Chief Financial Officer
	
	PURCHASER:
	
	  

	Scott Minick

  
 9 

 STOCK POWER 
 (Scott Minick) 
 FOR VALUE RECEIVED, Scott Minick hereby sells, assigns and
transfers to BIND Biosciences, Inc., a Delaware corporation (the “Company” ), a total of                  shares of the Common Stock of the Company
standing in his name on the books of the Company represented by stock certificate number              to be delivered herewith, and does hereby irrevocably constitute and appoint Foley Hoag
LLP as attorney to transfer said shares on the books of the Company with full power of substitution in the premises. 
 Dated: 

 

	
	  

	Scott Minick

 In the Presence of: 
  

	
	  

	Name:

 January 11, 2010 
  Page
 17
 of 7 
  

 Exhibit 3(d) 
 Promissory Note 

 PROMISSORY NOTE 

 

			
	 $533,005
	 	January 11, 2010

 FOR VALUE RECEIVED, Scott Minick (“Minick”) hereby promises to pay to the order of BIND
Biosciences, Inc., a Delaware corporation (“BIND”), the aggregate principal amount of Five Hundred Thirty-Three Thousand Five Dollars ($533,005), together with simple interest on the unpaid principal balance at the rate of
2.45% per annum, on or before January 11, 2018, or as earlier provided in Sections 1 and 3 below, subject to the terms set forth in this promissory note (this “Note”). All terms used herein without definition herein shall
have the meanings ascribed to them in that certain Employment Offer Letter, dated as of January 11, 2010 (the “Offer Letter”), by and among BIND and Minick. 

1. Payment of principal and interest shall be made in lawful money of the United States of America, by check sent to BIND at its
principal offices, or at such other place as BIND shall have designated to Minick in writing. All payments shall be credited first to the accrued interest then due and the remainder to principal. Minick may prepay this Note at any time without
premium or penalty; provided, however, that all prepayments of principal shall be applied in the reverse order of maturity. 
 2. In the event this Note is not paid when due, Minick agrees to pay, in addition to the principal and interest, all costs of collection, including reasonable attorneys’ fees, and interest thereon at
the rate set forth above. 
 3. The entire principal balance of this Note and any unpaid accrued interest shall become
immediately due and payable without notice or demand: 
 (a) Upon the appointment of a receiver of any of Minick’s
property, the assignment or trust mortgage for the benefit of Minick’s creditors, the commencement of any kind of insolvency proceedings under any bankruptcy or other law relating to the relief of debtors, or the entry of an order for relief
with respect to Minick in any proceeding pursuant to the United States Bankruptcy Code, as amended; 
 (b) Upon such date that
Minick resigns or is involuntarily terminated as an employee, consultant or a director of BIND if such resignation is not for Good Reason or such termination is with Cause; 
 (c) Six months following such date that Minick resigns or is involuntarily terminated as an employee, consultant or a director of BIND if such resignation is for Good Reason or such termination is without
Cause; or 
 (d) Immediately prior to BIND’s filing of a registration statement with the Securities and Exchange Commission
pursuant to Section 12 of the Securities Exchange Act of 1934. 
 4. No course of dealing of BIND nor any failure or delay
by BIND to exercise any right, power or privilege under this Note shall operate as a waiver hereunder or thereunder and any single or partial exercise of any such right, power or privilege shall not preclude any later exercise thereof or any
exercise of any other right, power or privilege hereunder or thereunder. 

  

 
Minick and every maker, endorser and guarantor of this Note or the obligations represented hereby waives presentment, demand, notice, protest and all other demands and notices in connection with
the delivery, acceptance, performance, default or enforcement of this Note, assents to any extension or postponement of the time of payment or any other indulgence, to any substitution, exchange or release of collateral and to the addition or
release of any other party or person primarily or secondarily liable. No covenant, obligation or other provision of this Note may be waived, and no consent contemplated hereby may be given, other than in a writing signed by BIND. BIND shall have
full recourse against Minick, and shall not be required to proceed against any collateral securing this Note in the event of default. 
 5. The provisions of this Note shall be governed by, and construed and enforced in accordance with, the substantive laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts
of laws. This Note may not be changed or terminated orally. 
 *    *    * 

IN WITNESS WHEREOF, the parties have executed this Promissory Note as an instrument under seal as of the date first above written.

  

			
	BIND BIOSCIENCES, INC.
		
	By:	 	  

	Name:	 	Andrea Franz
	Title:	 	Chief Financial Officer
	
	BORROWER:
	
	  

	Scott Minick
		
	Address:	 	  

		 	  

		 	  

  

					
	 

	  	                 BIND Therapeutics,
Inc.
                 325 Vassar Street

                Cambridge, MA 02139
	  	 www.bindtherapeutics.com
 phone 617.491.3400
 fax 617.491.0351

 August 28, 2013 
 Mr. Scott Minick 
 69 Wellington Avenue 

San Anselmo, CA 94960 
  

	 	Re:	Employment Letter 

 Dear Scott:

 Reference is made to that certain employment offer letter, dated as of January 11, 2010, by and between BIND
Therapeutics, Inc., formerly known as BIND Biosciences, Inc. (the “Company”), and you (the “Employment Letter”) and (ii) that certain Employee Confidentiality, Non-competition and Assignment of Intellectual
Property Agreement, dated as of January 11, 2010, by and between you and the Company (the “NDA”). 
 The
first two sentences of Section 3(e) of the Employment Letter are hereby amended and restated to read as follows: 
 “If
the Company terminates your employment without Cause or you resign your employment for Good Reason (in either event, a “Qualifying Termination”), subject to your execution of a release acceptable to the Company (the
“Release”) within the 30-day period following your Separation from Service, the expiration of any revocation period provided in the Release and your continued compliance with the terms of the NDA, the Company will pay you an amount
equal to your then-current base salary rate for a period of twelve (12) months (the “Severance Amount”); provided that the Severance Amount will be increased by the amount of the annual bonus you earned for the year prior to
the year of your termination of employment, if any, if the Qualifying Termination occurs within the three (3) months immediately preceding or the twelve (12) months immediately following a Change of Control. The Severance Amount will be
paid in substantially equal installments in accordance with the Company’s ordinary payroll practices over twelve (12) months (the “Severance Period”), beginning on the first payroll date following the date that is 40 days
after the date of your Separation from Service. 

 If the Qualifying Termination occurs within the three (3) months immediately preceding
or the twelve (12) months immediately following a Change of Control, then each outstanding equity award held by you that was granted on or after September 1, 2013, including, without limitation, each stock option, shall immediately vest
and, if applicable, become exercisable with respect to one hundred percent (100%) of the shares of Company common stock subject thereto. The vesting of each equity award granted prior to September 1, 2013 shall accelerate in accordance
with the terms and conditions of the agreement evidencing such award. 
 In addition, if you timely elect continued group
medical insurance coverage pursuant to COBRA, the Company will reimburse you for the applicable premiums for you and your eligible dependents during the period commencing on the date of your Separation from Service and ending on the earliest to
occur of (a) the final day of the Severance Period, (b) the date you and/or your eligible dependents are no longer eligible for COBRA and (c) the date you become eligible to receive medical insurance coverage from a subsequent
employer. Notwithstanding the foregoing, if the Company determines that it cannot provide such reimbursement of premiums to you without potentially violating applicable law, the Company shall in lieu thereof provide to you a taxable monthly payment
in an amount equal to the monthly COBRA premium that you would be required to pay to continue your group medical insurance coverage in effect on the date of your termination of employment (based on the premium for the first month of COBRA coverage),
which payment will be made regardless of whether you elect COBRA continuation coverage and will commence in the month following the month in which your Separation from Service occurs and end on the earliest to occur of (x) the final day of the
Severance Period, (y) the date you and/or your eligible dependents are no longer eligible for COBRA and (z) the date you become eligible to receive medical insurance coverage from a subsequent employer. 

Notwithstanding anything herein to the contrary, in the event that any compensation or benefit that constitutes “nonqualified
deferred compensation” within the meaning of Section 409A of the Code becomes payable upon the occurrence of a Change of Control, such compensation or benefit shall not be paid unless such Change of Control constitutes a “change in
control event” within the meaning of Section 409A of the Code.” 
 For purposes of this letter, the terms
“Cause,” “Good Reason” and “Change of Control” shall have the meanings set forth in the Employment Letter. The term “Separation from Service” means a “separation from
service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). Each installment payment provided under this letter or the Employment Letter shall at all times be considered a
separate and distinct payment for purposes of Section 409A of the Code. Notwithstanding anything in this letter or the Employment Letter to the contrary, to the extent required to avoid a prohibited distribution under Section 409A of the
Code, the benefits provided under this letter or the Employment Letter will not be provided to you until the earlier of (a) the expiration of the six-month period measured from the date of your Separation from Service with the Company or
(b) the date of your death. Upon the first business day after expiration of the relevant period, all payments delayed pursuant to the preceding sentence will be paid in a lump sum and any remaining payments due will be paid as otherwise
provided herein or in the Employment Letter. 

  
 2 

 Any successor to the Company (whether direct or indirect and whether by purchase, merger,
consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this letter and the Employment Letter and agree expressly to perform the obligations under this this
letter and the Employment Letter in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this letter and the Employment Letter, the term
“Company” shall include any successor to the Company’s business and/or assets which executes and delivers the assumption agreement described in the preceding sentence or which becomes bound by the terms of this letter and the
Employment Letter by operation of law. No provision of this letter or the Employment Letter shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by you and by an authorized officer
of the Company (other than you). No waiver by either party of any breach of, or of compliance with, any condition or provision of this letter or the Employment Letter by the other party shall be considered a waiver of any other condition or
provision or of the same condition or provision at another time. This letter and the Employment Letter represent the entire understanding of the parties hereto and thereto with respect to the subject matter hereof and thereof and supersede all prior
arrangements and understandings regarding same. The validity, interpretation, construction and performance of this letter and the Employment Letter shall be governed by the laws of the Commonwealth of Massachusetts without regard to conflicts of
law. The invalidity or unenforceability of any provision or provisions of this letter or the Employment Letter shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. This letter
may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument. 
 Except as expressly set forth in this letter, the Employment Letter and the NDA shall remain unchanged and shall continue in full force and effect according to their respective terms. 

 

			
	Sincerely,
	
	BIND THERAPEUTICS, INC.
		
	By:	 	/s/ Andrew Hirsch
	Name:	 	Andrew Hirsch
	Title:	 	Chief Financial Officer

  

	
	Acknowledged and Agreed:
	
	/s/ Scott Minick
	Scott Minick

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]